文献速递心力衰竭与心肌病

血浆TMAO联合NT-proBNP对缺血性心力衰竭患者预后及住院时长的预测价值

[Predictive value of plasma TMAO combined with NT-proBNP on the prognosis and length of hospitalization of patients with ischemic heart failure].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该前瞻性队列研究纳入189例缺血性心力衰竭患者,按血浆TMAO和NT-proBNP水平分为三组,随访中位3.0年。结果显示高TMAO+高NT-proBNP组全因死亡风险最高,且两标志物联合对全因死亡有良好预测价值,并与住院时长正相关。

要点

  • 高TMAO+高NT-proBNP组全因死亡风险显著增高,多因素校正后HR=3.11。
  • TMAO联合NT-proBNP预测全因死亡的AUC=0.727,敏感度55.0%,特异度83.1%。
  • 两标志物均升高与住院时长正相关(r=0.191),但与住院费用无关。

核心结论

  • TMAO联合NT-proBNP对缺血性心力衰竭患者预后具有较好预测价值。
  • 两种生物标志物均升高的患者全因死亡风险最高,且住院时间更长。

研究设计与样本

  • 前瞻性队列研究,连续入选2016年3月至2020年12月在广东省人民医院心内科住院的缺血性心力衰竭患者189例。
  • 患者左心室射血分数<45%,男性157例(83.1%),年龄(64.0±10.5)岁。
  • 按TMAO及NT-proBNP水平分为低TMAO+低NT-proBNP组50例、高TMAO或高NT-proBNP组89例、高TMAO+高NT-proBNP组50例。
  • 随访中位时间3.0年,以全因死亡为观察终点。

主要发现

  • 随访期间共70例(37.0%)死亡,高TMAO+高NT-proBNP组27例(54.0%)、高TMAO或高NT-proBNP组29例(32.6%)、低TMAO+低NT-proBNP组14例(28.0%)。
  • 三组间全因死亡率差异有统计学意义(log-rank P<0.001)。
  • 多因素Cox回归校正一般情况、既往史、入院病因、实验室及超声心动图结果、住院治疗情况后,高TMAO+高NT-proBNP组全因死亡风险最高(HR=3.11,95%CI 1.53~6.31,P<0.001)。
  • ROC曲线分析显示TMAO联合NT-proBNP预测全因死亡的AUC=0.727(95%CI 0.640~0.813),敏感度55.0%,特异度83.1%。
  • Spearman相关分析显示TMAO联合NT-proBNP水平与住院时长呈正相关(r=0.191,P=0.009),与住院费用无相关性(r=0.030,P=0.686)。

临床怎么用

  • 对缺血性心力衰竭患者可检测血浆TMAO和NT-proBNP,联合用于风险分层。
  • 两标志物均升高的患者应识别为全因死亡高危人群,加强随访管理。
  • 两标志物均升高提示可能延长住院时间,可优化住院资源配置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the value of the assessment of plasma trimethylamine N-oxide (TMAO) combined with N-terminal pro-B-type natriuretic peptide (NT-proBNP) on predicting the all-cause mortality, length of hospitalization, and hospital cost in ischemic heart failure (IHF) patients. Methods: This prospective cohort study included 189 patients (157 males, mean age (64.0±10.5) years) with a left ventricular ejection fraction<45% caused by coronary artery disease, who hospitalized in our department from March 2016 to December 2020. Baseline data, including demographics, comorbid conditions and laboratory examination, were analyzed. The cumulative rate of all-cause mortality was evaluated using the Kaplan-Meier method and compared between the groups according to the log-rank test. Relative risks were reported as hazard ratios (HR) and 95% confidence interval (95%CI) calculated using the Cox proportional-hazards analysis, with stepwise adjustment for covariables. Spearman correlation analysis was then performed to determine the relationship between TMAO combined with NT-proBNP and length of hospitalization and hospital cost. Results: There were 50 patients in the low TMAO+low NT-proBNP group, 89 patients in high TMAO or high NT-proBNP group, 50 patients in high TMAO+high NT-proBNP group. The mean follow-up period was 3.0 years. Death occurred in 70 patients (37.0%), 27 patients (54.0%) in high TMAO+high NT-proBNP group, 29 patients (32.6%) in high TMAO or high NT-proBNP group and 14 patients (28.0%) in low TMAO+low NT-proBNP group. TMAO, in combination with NT-proBNP, improved all-cause mortality prediction in IHF patients when stratified as none, one or both biomarker(s) elevation, with the highest risk of all-cause mortality in high TMAO+high NT-proBNP group (HR=3.62, 95%CI 1.89-6.96, P<0.001). ROC curve analysis further confirmed that TMAO combined with NT-proBNP strengthened the prediction performance on the risk of all-cause death (AUC=0.727(95%CI 0.640-0.813), sensitivity 55.0%, characteristic 83.1%). Spearman correlation analysis showed that IHF patients with high TMAO and high NT-proBNP were positively associated with longer duration of hospitalization (r=0.191,P=0.009), but not associated with higher hospital cost (r=0.030, P=0.686). Conclusions: TMAO combined with NT-proBNP are valuable prediction tool on risk stratification of patients with IHF, and those with two biomarkers elevation face the highest risk of mortality during follow-up period, and are associated with the longer hospital stay. 目的: 评估血浆氧化三甲胺(TMAO)联合N末端B型利钠肽原(NT-proBNP)对缺血性心力衰竭(IHF)患者预后的预测价值,及其与患者住院时长和费用的相关性。 方法: 该研究为诊断性试验。连续入选2016年3月至2020年12月在广东省人民医院心内科住院的IHF患者,根据TMAO及NT-proBNP水平将患者分为3组,即低TMAO+低NT-proBNP组、高TMAO或高NT-proBNP组和高TMAO+高NT-proBNP组。通过电子病历系统收集患者的基线临床资料。通过电话进行随访,随访时间=死亡日期(或最后一次随访日期)-出院日期,以全因死亡作为观察终点。采用Kaplan-Meier生存分析分析各组患者的全因死亡率,多因素Cox回归模型计算各组患者的死亡风险比(HR),受试者工作特征(ROC)曲线评估TMAO联合NT-proBNP对IHF患者全因死亡的预测价值,Spearman相关分析评估TMAO及NT-proBNP水平与住院时长、住院费用的相关性。 结果: 研究最终入选患者189例,男性157例(83.1%),年龄(64.0±10.5)岁,其中低TMAO+低NT-proBNP组50例、高TMAO或高NT-proBNP组89例、高TMAO+高NT-proBNP组50例。随访中位时间3.0年,共70例(37.0%)患者死亡,其中高TMAO+高NT-proBNP组27例(54.0%)、高TMAO或高NT-proBNP组有29例(32.6%)、低TMAO+低NT-proBNP组有14例(28.0%)。Kaplan-Meier生存分析结果显示,三组间全因死亡率差异有统计学意义(log-rank P<0.001)。多因素Cox回归分析结果显示,校正了患者的一般情况、既往史、入院病因、实验室及彩色超声心动图检查结果、住院治疗情况后,高TMAO+高NT-proBNP组患者的全因死亡风险仍为最高(HR=3.11,95%CI 1.53~6.31,P<0.001)。ROC曲线分析结果显示TMAO联合NT-proBNP对于IHF患者全因死亡有良好的预测价值(AUC=0.727,95%CI 0.640~0.813,敏感度为55.0%,特异度为83.1%)。Spearman相关分析结果显示,血浆TMAO联合NT-proBNP水平与IHF患者住院时长呈正相关(r=0.191,P=0.009),与住院费用未见相关性(r=0.030,P=0.686)。 结论: TMAO联合NT-proBNP对IHF患者预后具有较好的预测价值,两种生物标志物均升高的患者全因死亡风险较高,同时两种生物标志物升高的IHF患者住院时间更长,但对住院费用的影响不大。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qiu, Xiao, Xia, et al. [Predictive value of plasma TMAO combined with NT-proBNP on the prognosis and length of hospitalization of patients with ischemic heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35856225. doi:10.3760/cma.j.cn112148-20210920-00807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。